Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axonyx’ Phenserine Could Be First Alzheimer’s Agent Targeting Beta-Amyloid Plaques To Reach FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III trials for the acetylcholinesterase inhibitor are expected to complete in December 2004. Beta-amyloid is a primary therapeutic target as companies race to develop disease-modifying therapies that go beyond the symptom relief provided by current drugs. Statins and NSAIDs are also being examined for their potential to alter the course of AD.

You may also be interested in...



Axonyx’ Phenserine Fails Pivotal Alzheimer’s Trial Due To High Placebo Response

Development program for the potential disease-modifying Alzheimer’s agent will continue, the firm says. A second pivotal trial began in June 2004. Interim results from a Phase IIb mechanistic study are expected in March.

Axonyx’ Phenserine Fails Pivotal Alzheimer’s Trial Due To High Placebo Response

Development program for the potential disease-modifying Alzheimer’s agent will continue, the firm says. A second pivotal trial began in June 2004. Interim results from a Phase IIb mechanistic study are expected in March.

Novartis, Cephalon Disease-Modifying Parkinson's Drugs Near Late-Stage Development

Novartis' TCH-346 is slated to enter Phase III in the second half of the year; Cephalon/Lundbeck's CEP-1347 is in Phase II/III. Both drugs claim inhibition of neuronal cell death as the primary mechanism, but will need long-term trials for disease-modification claim.

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel